ArticleFrontiers in genetics2026
Feasibility of IG and TCR rearrangements quantification in ctDNA for monitoring clinical response in pediatric lymphomas.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lymphomas are malignancies of the lymphatic system characterized by clonal rearrangements of immunoglobulin (Ig) and T-cell receptor (TCR) genes. While diagnosis relies on tissue biopsy, circulating tumor DNA (ctDNA) analysis offers a minimally invasive approach for real-time disease monitoring. This study evaluated next-generation sequencing (NGS) for the detection and quantification of Ig and TCR rearrangements in ctDNA from pediatric lymphoma patients. Methods: Forty cases (21 Hodgkin and 19 non-Hodgkin lymphomas) were analyzed using NGS with BIOMED-2 and EuroClonality primers. Results: Clonal rearrangements were identified in tumor DNA from 23 patients, yielding 54 rearrangements. For 19 patients, paired tumor (gDNA) and plasma (cfDNA) at diagnosis samples were analyzed. Most of the rearrangements identified in these tumor samples (n = 48) were found in the corresponding diagnostic cfDNA (n = 43, 89.6%). Patients who relapsed showed significantly higher cfDNA levels at diagnosis, and in one case, ctDNA increase preceded clinical or radiological relapse. Discussion: These findings support liquid biopsy as a feasible tool for monitoring disease dynamics and early relapse detection in pediatric lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.